|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12N 5/079 | |
| G01N 33/50 | |||
| C12Q 1/37 |
| (11) | Number of the document | 2406371 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10709359.3 |
| Date of filing the European patent application | 2010-03-12 | |
| (97) | Date of publication of the European application | 2012-01-18 |
| (45) | Date of publication and mention of the grant of the patent | 2018-05-09 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2010/027242 |
| Date | 2010-03-12 |
| (87) | Number | WO 2010/105234 |
| Date | 2010-09-16 |
| (30) | Number | Date | Country code |
| 160199 P | 2009-03-13 | US |
| (72) |
JACKY, Birgitte, P.S., US
WANG, Joanne, US
ZHU, Hong, US
HODGES, D., Dianne, US
FERNANDEZ-SALAS, Ester, US
|
| (73) |
ALLERGAN, INC.,
2525 Dupont Drive, Irvine, CA 92612,
US
|
| (54) | CELLS USEFUL FOR IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS |
| CELLS USEFUL FOR IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS |